Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX506
- Development stage
- Preclinical
- Lead developer
- DermaXon
- Modality
- Small Molecules
01
Overview
DX506 is a preclinical-stage small molecule therapeutic being developed by DermaXon for the treatment of interferonopathies and coronavirus infections (including COVID-19). Interferonopathies are a group of rare genetic disorders, such as Aicardi-Goutières Syndrome, characterized by chronic overproduction of type I interferons. DX506 is designed to target innate immune pathways responsible for this dysregulation. In the context of coronavirus, the drug is intended to mitigate the hyper-inflammatory response or "cytokine storm" that can lead to severe disease. As of 2021, DX506 was listed in DermaXon's pipeline as a preclinical asset.
Beyond the preview
Go deeper on DX506.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX506.